Stocks and Investing
Stocks and Investing
Fri, May 13, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Barcus Maintained (VINC) at Strong Buy with Decreased Target to $11 on, May 13th, 2022
Matthew Barcus of Chardan Capital, Maintained "Vincerx Pharma, Inc." (VINC) at Strong Buy with Decreased Target from $14 to $11 on, May 13th, 2022.
Matthew has made no other calls on VINC in the last 4 months.
There is 1 other peer that has a rating on VINC. Out of the 1 peers that are also analyzing VINC, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $28 on, Wednesday, March 30th, 2022
Contributing Sources